









Markets
/
Stocks
/
nasdaq-auph
/

Aurinia Pharmaceuticals Inc

AUPH

15.350USD

+0.130+0.85%

Close 11/14, 16:00（ET）Quotes delayed by 15 min

2.02BMarket Cap

26.00P/E TTM



Aurinia Pharmaceuticals Inc

15.350

+0.130+0.85%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Aurinia Pharmaceuticals Inc

Currency: USD Updated: 2025-11-13

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aurinia Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

56 / 406

Overall Ranking

149 / 4603

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.714

Target Price

+1.12%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aurinia Pharmaceuticals Inc Highlights

StrengthsRisks

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 75.43% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 26.45, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 58.52M shares, decreasing 18.00% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 126.00K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.56.

Financial Health

Currency: USD Updated: 2025-11-13

The company's current financial score is 9.03, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 73.47M, representing a year-over-year increase of 8.41%, while its net profit experienced a year-over-year increase of 119.87%.

Score

Industry at a Glance

Previous score

9.03

Change



Financials

7.49

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

9.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.96

Key Metrics

Free cash flow

No Data

Aurinia Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-13

The company’s current valuation score is 5.10, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 26.45, which is 744.23% below the recent high of 223.33 and 351.21% above the recent low of -66.45.

Score

Industry at a Glance

Previous score

5.10

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 56/406

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-13

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Aurinia Pharmaceuticals Inc is 15.00, with a high of 21.00 and a low of 12.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

15.714

Target Price

+3.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Aurinia Pharmaceuticals Inc

AUPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-13

The company’s current price momentum score is 9.07, which is higher than the Biotechnology & Medical Research industry's average of 6.59. Sideways: Currently, the stock price is trading between the resistance level at 17.18 and the support level at 12.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.19

Change

-0.12

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.459

Buy

RSI(14)

71.009

Buy

STOCH(KDJ)(9,3,3)

73.021

Neutral

ATR(14)

0.896

High Vlolatility

CCI(14)

74.408

Neutral

Williams %R

20.047

Buy

TRIX(12,20)

1.135

Sell

StochRSI(14)

11.698

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

15.336

Buy

MA10

14.713

Buy

MA20

13.427

Buy

MA50

12.597

Buy

MA100

11.416

Buy

MA200

9.728

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-13

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.13. The latest institutional shareholding proportion is 44.38%, representing a quarter-over-quarter decrease of 24.45%. The largest institutional shareholder is The Vanguard, holding a total of 1.53M shares, representing 1.16% of shares outstanding, with 3.96% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Tang Capital Management, LLC

10.03M

ILJIN SNT Co., Ltd.

6.54M

-13.10%

BlackRock Institutional Trust Company, N.A.

6.46M

-13.48%

New Enterprise Associates (NEA)

3.97M

State Street Investment Management (US)

2.80M

-1.97%

Morgan Stanley & Co. LLC

1.70M

-2.10%

Armistice Capital LLC

1.63M

-67.41%

The Vanguard Group, Inc.

Star Investors

1.69M

-12.90%

Geode Capital Management, L.L.C.

1.58M

-9.07%

Qube Research & Technologies Ltd

1.24M

+45.13%

Risk Assessment

Currency: USD Updated: 2025-11-13

The company’s current risk assessment score is 5.96, which is higher than the Biotechnology & Medical Research industry's average of 3.46. The company's beta value is 1.44. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.